Featured Clinical Trials Supported by the National Cancer Institute
Today, thousands of cancer clinical trials are under way in the United States. Clinical trials answer vital research questions that lead to better screening, prevention, diagnosis, and treatment options for all cancers. This section highlights NCI-supported cancer trials and demonstrates the breadth of clinical cancer research supported by the Institute.
To find other cancer trials open to enrollment:
- Call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237) for information about trials all across the country. The call is toll-free and completely confidential.
- Use the clinical trials search form to look online for trials listed on NCI's Cancer.gov website. The form has a Help link for tips about searching for clinical trials.
- For information about cancer trials taking place on the National Institutes of Health campus in Bethesda, Maryland, call NCI’s Clinical Trials Referral Office at 1-888-NCI-1937 (1-888-624-1937). The call is toll-free and completely confidential.
(Posted: 05/27/2008) - In this trial, patients who have a history of colorectal adenoma--noncancerous growths (polyps) found in the colon or rectum that can be precursors to colorectal cancer--will be randomly assigned to receive daily selenium supplements or a placebo for 3 or 5 years.
Cediranib for Androgen-Independent Prostate Cancer
(Posted: 04/29/2008) - In this trial, men with metastatic, androgen-independent prostate cancer whose cancer has continued to progress on docetaxel will take oral cediranib daily.
Combination Therapy for Advanced Melanoma
(Posted: 11/01/2005, Updated: 04/24/2008) - In this clinical trial, researchers are testing chemotherapy with the drugs carboplatin and paclitaxel in combination with a new drug called sorafenib (BAY 43-9006) in patients with advanced melanoma.
Batracylin for Patients with Advanced Solid Tumors or Lymphoma
(Posted: 04/01/2008) - In this phase I trial, patients with solid tumors or lymphomas for which standard therapies do not exist or are of minimum benefit and who are slow acetylators, as determined by a blood test, will be treated with increasing doses of the drug batracylin.
Chemoprevention Trial for Head and Neck Cancer
(Posted: 02/01/2005, Updated: 03/05/2008) - In this study, researchers are investigating the ability of pioglitazone, a drug used to treat type II diabetes, to reverse leukoplakia and prevent it from developing into head and neck cancer.